Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
19
09
2022
pubmed:
13
11
2022
medline:
12
1
2023
entrez:
12
11
2022
Statut:
ppublish
Résumé
The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilized MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid, single-vial formulation has been developed to simplify administration and prevent reconstitution errors. We present pooled safety data from two randomized, controlled, observer-blind phase 2b clinical trials, in which the fully liquid presentation was compared with the licensed presentation. This is a post hoc analysis of two studies, in which safety data from participants aged 10-40 years who received one dose of either liquid MenACWY-CRM (1337 participants; MenACWY liquid group) or licensed MenACWY-CRM (1332 participants; MenACWY licensed group) were pooled. Frequencies were calculated for solicited adverse events (AEs) during 7 days post-vaccination and unsolicited AEs, including medically attended AEs and serious AEs (SAEs), during the 6-month safety follow-up period. Analysis results are presented by vaccine group, overall and by age category (10-17 and 18-40 years). Overall, AEs solicited for collection during the first 7 days after vaccination were reported by similar percentages of participants (69.2%, MenACWY liquid; 68.2%, MenACWY licensed), and were generally mild/moderate in intensity. Solicited local AEs were reported by 46.0% of the MenACWY liquid group and 43.5% of the MenACWY licensed group and solicited systemic AEs by 55.2 and 54.1%, respectively. During the 6-month post-vaccination period, unsolicited AEs were reported by 32.2 and 31.2% of the MenACWY liquid group and MenACWY licensed group, respectively, and medically attended AEs by 18.6 and 17.3%, respectively. Overall, 14 participants in each group (1.0 and 1.1%, respectively) reported SAEs, none of which was considered vaccine-related by the investigator. The safety profiles of both MenACWY-CRM presentations were similar for each age group and overall. This pooled analysis shows the safety profile of fully liquid MenACWY-CRM is comparable with that of the currently licensed vaccine presentation. ClinicalTrials.gov Identifiers: NCT03652610 (August 29, 2018), NCT03433482 (14 February 2018).
Identifiants
pubmed: 36369456
doi: 10.1007/s40264-022-01242-8
pii: 10.1007/s40264-022-01242-8
pmc: PMC9829640
doi:
Substances chimiques
MenACWY-CRM vaccine
0
Banques de données
ClinicalTrials.gov
['NCT03652610', 'NCT03433482', 'NCT03652610']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-108Informations de copyright
© 2022. GSK.
Références
Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82. https://doi.org/10.1016/j.vaccine.2019.04.020 .
doi: 10.1016/j.vaccine.2019.04.020
Olbrich KJ, Müller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–38. https://doi.org/10.1007/s40121-018-0213-2 .
doi: 10.1007/s40121-018-0213-2
Parikh S, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81:483–98. https://doi.org/10.1016/j.jinf.2020.05.079 .
doi: 10.1016/j.jinf.2020.05.079
Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020. https://doi.org/10.3390/microorganisms8101521 .
doi: 10.3390/microorganisms8101521
Martinón-Torres F, Taha MK, Knuf M, Abbing-Karahagopian V, Pellegrini M, Bekkat-Berkani R, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2021. https://doi.org/10.1080/20477724.2021.1972663 .
doi: 10.1080/20477724.2021.1972663
Keshavan P, Pellegrini M, Vadivelu-Pechai K, Nissen M. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Rev Vaccines. 2018;17(10):865–80. https://doi.org/10.1080/14760584.2018.1521280 .
doi: 10.1080/14760584.2018.1521280
Ruiz Garcia Y, Abitbol V, Pellegrini M, Bekkat-Berkani R, Soumahoro L. A decade of fighting invasive meningococcal disease: a narrative review of clinical and real-world experience with the MenACWY-CRM conjugate vaccine. Infect Dis Ther. 2021. https://doi.org/10.1007/s40121-021-00519-2 .
doi: 10.1007/s40121-021-00519-2
Bröker M, Dull PM, Rappuoli R, Costantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine. 2009;27(41):5574–80. https://doi.org/10.1016/j.vaccine.2009.07.036 .
doi: 10.1016/j.vaccine.2009.07.036
Berti F, Romano MR, Micoli F, Pinto V, Cappelletti E, Gavini M, et al. Relative stability of meningococcal serogroup A and X polysaccharides. Vaccine. 2012;30(45):6409–15. https://doi.org/10.1016/j.vaccine.2012.08.021 .
doi: 10.1016/j.vaccine.2012.08.021
Beresford NJ, Martino A, Feavers IM, Corbel MJ, Bai X, Borrow R, et al. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
doi: 10.1016/j.vaccine.2017.03.066
Su JR, Miller ER, Duffy J, Baer BM, Cano MV. Notes from the field: administration error involving a meningococcal conjugate vaccine–United States, March 1, 2010–September 22. MMWR Morb Mortal Wkly Rep. 2016;65(6):161–2. https://doi.org/10.15585/mmwr.mm6506a4 .
doi: 10.15585/mmwr.mm6506a4
Vandermeulen C, Leroux-Roels I, Vandeleur J, Staniscia T, Girard G, Ferguson M, et al. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: results from a multicentre, randomised, controlled, observer-blind study. Vaccine. 2021;39(45):6628–36. https://doi.org/10.1016/j.vaccine.2021.09.068 .
doi: 10.1016/j.vaccine.2021.09.068
Díez-Domingo J, Tinoco JC, Poder A, Dinleyici EC, Nell H, Salamanca de la Cueva I, et al. Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults. Hum Vaccin Immunother. 2022;18(1):1981085. https://doi.org/10.1080/21645515.2021.1981085 .
doi: 10.1080/21645515.2021.1981085
Bröker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM
doi: 10.2147/idr.s12716
Lalwani S, Agarkhedkar S, Gogtay N, Palkar S, Agarkhedkar S, Thatte U, et al. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. Int J Infect Dis. 2015;38:36–42. https://doi.org/10.1016/j.ijid.2015.07.003 .
doi: 10.1016/j.ijid.2015.07.003
Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49(1):e1-10. https://doi.org/10.1086/599117 .
doi: 10.1086/599117
Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560–9. https://doi.org/10.1016/j.vaccine.2020.03.017 .
doi: 10.1016/j.vaccine.2020.03.017